Soligenix, Inc. reported a net loss of $11.1 million for the fiscal year ending December 31, 2025, an increase of 34% compared to a net loss of $8.3 million in 2024. The company did not generate any revenue during 2025, a significant decline from $119,371 in the previous year, primarily due to the conclusion of a zero-margin grant for the HyBryte™ investigator-initiated study. Research and development expenses rose by 43% to $7.5 million, driven by costs associated with ongoing clinical trials for its product candidates, including the second Phase 3 study of HyBryte™ for cutaneous T-cell lymphoma (CTCL) and a Phase 2a study for Behçet’s Disease (SGX945).
The company’s financial position remains precarious, with cash and cash equivalents totaling approximately $7.9 million as of December 31, 2025, compared to $7.8 million in 2024. Soligenix has raised concerns about its ability to continue as a going concern, as it does not have sufficient cash to fund operations for the next 12 months without additional financing. To address this, the company plans to secure additional capital through public or private equity offerings, government contracts, and sales of common stock under an At Market Issuance Sales Agreement, which could yield up to $3.5 million.
Operationally, Soligenix is focused on advancing its two business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment is developing HyBryte™, a photodynamic therapy for CTCL, and expanding its use into psoriasis with SGX302. The Public Health Solutions segment includes vaccine candidates such as RiVax® for ricin toxin exposure and SGX943 for antibiotic-resistant infections. The company has received government funding to support these initiatives, but the sustainability of its operations heavily relies on continued government support and successful clinical trial outcomes.
As of March 24, 2026, Soligenix had 10,306,079 shares of common stock outstanding, with a market value of approximately $4.6 million. The company’s stock has experienced significant volatility, with prices ranging from $1.02 to $19.20 over the past year. The board of directors has determined that several members are independent, and the company has established various committees to oversee governance and risk management. Despite these efforts, the company faces challenges in securing additional funding and achieving market acceptance for its product candidates, which could impact its long-term viability.
About SOLIGENIX, INC.
Soligenix, Inc. is a late-stage biopharmaceutical company developing treatments for rare diseases and infectious threats. Its core segments focus on innovative therapies for cutaneous T-cell lymphoma, psoriasis, and inflammatory diseases, utilizing proprietary photodynamic and immune-modulating technologies. The company also advances vaccine platforms targeting biothreats like ricin, Ebola, and COVID-19, leveraging government grants and strategic partnerships to bring novel, targeted therapeutics and vaccines to global markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.